12th IAS Conference on HIV Science (IAS 2023): further reports
1 October 2023. Related: Conference reports, Conference index, IAS 2023 Brisbane.
23 – 26 July 2023, Brisbane, Australia
Introduction
This issue of HTB includes further reports from IAS 2023 was held in Brisbane, Australia, and as a hybrid conference.
The meeting had a strong programme that included latest scientific progress in HIV treatment.
The open access programme links to abstracts online and includes rapporteur summaries. It doesn’t currently link to any webcasts, and satellite and plenary sessions don’t include abstracts for these talks:
https://programme.ias2023.org
Abstracts are also available from a separate URL:
https://programme.ias2023.org/Abstract/Index
Abstract book (PDF):
https://www.iasociety.org/sites/default/files/IAS2023/abstract-book/IAS_2023__Abstracts.pdf
The following reports are included in this issue of HTB.
- Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings
- IAS 2023: LA-CAB/RPV as first-line ART and implementation studies
- bNAbs for prevention and cure: antiviral and vaccine-like responses
- High rates of re-suppression with dolutegravir in the ADVANCE study
- In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
- Bictegravir use in pregnancy: more data needed